THE DEAL: Thermo Fisher Scientific Inc. said Monday that it plans to pay about $13.6 billion, or $76 per share, for Life Technologies Corp.
THE STRATEGY. The deal positions Thermo Fisher to benefit from the expected growth of personalized medicine, which uses genetic analysis to tailor treatments to patients. Analysts also expect the companies to reap savings from the combination and gain leverage in negotiating with suppliers.
SALES APPEAL: Life Technologies delves into genetic analysis, stem cell therapies and chemicals used in forensics and food safety. Its next-generation DNA sequencing is designed to sequence a person's entire genome in one day for $1,000.